Antisense is the non-coding strand in double-stranded DNA. The antisense strand serves as the template for mRNA synthesis.
Three grants for research that could transform cancer therapies have been awarded by the AACR-MPM Oncology Charitable Foundation Transformative Cancer Research Grants Program, an innovative partnership between the American Association for Cancer Research and the UBS Oncology Impact Fund managed by MPM Capital.
Many patients with multiple myeloma, a type of blood cancer, eventually develop resistance to one treatment after another. That's in part because cancer stem cells drive the disease -- cells that continually self-renew. If a therapy can't completely destroy these malignant stem cells, the cancer is likely to keep coming back.
Ultra-small nanomedicines of approximately 18 nm were fabricated by dynamic ion-pairing between Y-shaped block copolymers and nucleic acid drugs, such as siRNA and antisense drugs.
Antisense oligonucleotides (ASO) hold great promise for pharmacotherapy. Now, researchers at Tokyo Medical and Dental University (TMDU) and Ionis Pharmaceuticals, advancing their earlier work on a heteroduplex oligonucleotide (HDO) model, have demonstrated augmentation of ASO-based drugs by replacing the RNA strand with DNA.
News-Medical talks to Dipanjan Pan about the development of a paper-based electrochemical sensor that can detect COVID-19 in less than five minutes.
Advances in scientific knowledge and drug development technology have provided an opportunity for new approaches to drug development, including the development of drugs for the treatment of rare diseases.
Cold Spring Harbor Laboratory (CSHL) scientists have discovered a gene-regulating snippet of RNA that may contribute to the spread of many breast cancers.
As the COVID-19 pandemic continues to spread across the world, testing remains a key strategy for tracking and containing the virus.
Adding exercise to a genetic treatment for myotonic dystrophy type 1 (DM1) was more effective at reversing fatigue than administering the treatment alone in a study using a mouse model of the disease.
The hunt for antivirals has reached an unprecedented pace in light of the coronavirus 2019 (COVID-19) pandemic. The causal agent for this disease – severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – has already infected over 52 million people worldwide, and has subsequently claimed over 1.3 million lives. However, among the innumerable promising drug candidates that help battle the virus and mitigate its damage, none have yet made it to the clinic.
The SARS-CoV-2 coronavirus RNA genome structure was studied in detail by researchers from the University of Groningen, the International Institute of Molecular and Cell Biology in Warsaw, and Leiden University.
Conducted by researchers in South Korea at the Institute for Basic Science and the International Vaccine Institute, a new study published on the preprint server bioRxiv in November 2020 describes the many host proteins that bind with the ribonucleic acid (RNA) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and regulate the replication of the virus.
Five research projects with exceptional promise to deliver new life-changing and health-altering therapies have received the inaugural Blavatnik Therapeutics Challenge Awards (BTCA) at Harvard Medical School.
A part of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral RNA is highly conserved. Researchers have used this as a target for designing antisense oligonucleotide gapmers to cleave the RNA and disrupt virus replication. Their research is published as a preprint on the online server bioRxiv in September 2020.
A recent study reveals how the non-structural protein 1 (NSP1) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) plays a crucial role in inhibiting the host cell protein synthesis but simultaneously facilitating the viral protein synthesis.
An investigational drug that targets an instigator of the TDP-43 protein, a well-known hallmark of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), may reduce the protein's buildup and neurological decline associated with these disorders, suggests a pre-clinical study from researchers at Penn Medicine and Mayo Clinic.
Researchers in Milan, Italy, have identified the presence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the heart tissue of deceased coronavirus disease 2019 (COVID-19) patients who had died from respiratory failure, without showing any signs of cardiac involvement.
Researchers at Osaka University identify vicious cycle involving RNA exosome that accelerates disease progression in FTLD/ALS
Every year, 1.1 million new cases of blood cancers are diagnosed worldwide. Presently, chemotherapy remains the most common and effective course of treatment.
Today, the U.S. Food and Drug Administration granted accelerated approval to Viltepso (viltolarsen) injection for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping.